DiaMedica Therapeutics (NASDAQ:DMAC) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research note released on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $7.00 target price on the stock. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.47) EPS.

Separately, Oppenheimer reaffirmed an outperform rating and set a $6.00 target price on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

DiaMedica Therapeutics Stock Down 1.8 %

DiaMedica Therapeutics stock opened at $4.42 on Monday. The stock has a market cap of $188.92 million, a P/E ratio of -7.89 and a beta of 1.48. DiaMedica Therapeutics has a twelve month low of $1.94 and a twelve month high of $4.95. The company’s 50-day moving average price is $3.99 and its two-hundred day moving average price is $3.27.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. Equities analysts anticipate that DiaMedica Therapeutics will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently made changes to their positions in the company. Magnolia Capital Advisors LLC acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $87,000. Paragon Associates & Paragon Associates II Joint Venture boosted its position in shares of DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of DiaMedica Therapeutics by 26.3% during the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after acquiring an additional 211,351 shares in the last quarter. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.